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ABSTRACT
Background    Recurrence of lung cancer after surgical 
resection is a major obstacle in the cure and long-term 
survival of patients and has become the most common 
cause of death. However, prognostic factors and efficacy 
of therapy after recurrence remain controversial. We 
evaluated the prognostic factors of post recurrence sur-
vival (PRS) in patients of resected stage I non-small cell 
lung cancer (NSCLC).
Methods    Of the 551 patients who underwent surgery 
for stage I NSCLC between 2005 and 2013, we reviewed 
89 (16.2%) patients who had recurrence. We examined 
PRS using the Kaplan–Meier method and multivariate 
Cox regression analyses.
Results    The median follow-up period after recurrence 
was 21.0 months. The median recurrence free interval 
(RFI) was 16.8 months. The 1-year PRS and 3-year PRS 
were 65.6% and 44.7%, respectively. Multivariate anal-
ysis revealed that size of primary lesion > 25 mm (P = 
0.048), RFI ≤ 17 months (P = 0.048) and no treatment 
for recurrence (P < 0.001) were independent poor-prog-
nosis factors of PRS. We further examined PRS in 66 
patients who underwent any post recurrence therapy. For 
the patients who underwent treatment after recurrence, 
bone metastasis (P = 0.025) and treatment without epi-
dermal growth factor receptor-tyrosine kinase inhibitors 
(EGFR-TKIs) (P = 0.049) were independent poor prog-
nostic factors. 
Conclusion    PRS may be associated with character-
istics of a recurrent lesion, including the biology of the 
recurrent tumor, RFI, recurrent site, the treatment for 
recurrence, rather than characteristics of primary lesion. 
Although further validation is needed, this information 
is important for the design of clinical trials for post-re-
currence therapy.
Key words    epidermal growth factor receptor tyrosine 
kinase inhibitors; non-small cell lung cancer; post recur-
rence survival; prognostic factor
Lung cancer is the leading cause of cancer deaths in Ja-
pan and around the world. Although surgical resection 
is the most appropriate choice of treatment for early 
stage non-small cell lung cancer (NSCLC),1 the recur-
rence rate of stage I NSCLC has been reported to be 
18.5%–28%.2–5 According to the Japanese Lung Cancer 
Registry Study, tumor recurrence remains a major cause 
of post-operative death.6 Despite the administration of 
multimodality therapy, including chemotherapy, ra-
diation therapy, or a combination of other therapeutic 
modalities, most lung cancer patients with postoperative 
recurrence have little possibility of cure.2, 7, 8 Although 
several studies have described prognostic factors for the 
post-recurrence survival (PRS) of patients with stage I or 
I–III NSCLC and for the PRS of lung adenocarcinoma 
patients,2–5, 7–14 the predictive prognostic factors for PRS 
of NSCLC remain controversial. The aim of this study 
was to evaluate the prognostic factors of PRS in patients 
with completely resected stage I NSCLC.  
MATERIALS AND METHODS
Of 551 patients who underwent complete resection for 
pathological stage I NSCLC between January 2005 and 
December 2013 at Tottori University Hospital (Yonago, 
Japan), we retrospectively analyzed the cases of the 89 
(16.2%) patients who developed postoperative recur-
rence. The following exclusion criteria were applied: in-
duction chemotherapy or radiation therapy or both; low-
grade pulmonary malignant tumor including carcinoid 
tumor; positive pleural lavage cytology; and death with-
in 30 days of the patient’s resection. Complete resection 
was defined as the demonstration of cancer free surgical 
margins including pleural lavage cytology, both grossly 
and histologically.
 Patients were followed up every 3 months in the 
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first 2 years after resection, then every 3–6 months 
thereafter. The follow-up procedures included physical 
examination, chest X-ray, hematological examination 
and serum tumor markers. Chest and abdomen comput-
ed tomography (CT) scans were performed every year. 
Whenever recurrent disease was suspected, magnetic 
resonance imaging (MRI) of the brain and positron 
emission tomography (PET) of the whole body were 
performed. After the initial diagnosis of recurrence, fur-
ther examination including contrast-enhanced CT, brain 
MRI and PET were performed to check for other meta-
static sites. 
 Tumor stage was determined based on the seventh 
TNM classification of lung cancer. The pathological 
diagnosis was performed using hematoxylin and eosin 
(H&E) stained sections according to the World Health 
Organizing classification for lung cancer. The date of 
recurrence was defined as the date when the physician 
recognized the recurrent disease, regardless of histolog-
ical or cytological confirmations. Elevation of the serum 
tumor markers alone did not define recurrence. Locore-
gional recurrence was defined as the recurrence in surgi-
cal margin, ipsilateral hemithorax, or mediastinal lymph 
nodes, and distant metastasis was defined as the recur-
rence in the contralateral hemithorax or extrathoracic 
organs. When there were simultaneous locoregional and 
distant recurrence, it was defined as distant metastasis. 
When a patient presented with a new histological type, 
or with clinical features consistent with a new primary 
lung cancer, it was defined as a second primary tumor. 
 RFI was defined as the time in months from the 
date of resection for primary lung cancer to the date of 
the initial recurrence. The length of PRS was defined as 
the time in months from the date of the initial relapse to 
the date of death from any cause or the date of which the 
patient was last known to be alive. 
 The Kaplan-Meier method was used for calculation 
of the PRS, and differences in survival were determined 
by log-rank test. The cut-off values of each continuous 
variable, such as age, tumor size, RFI and CEA were 
defined using ROC curve. AUC sensitivity and specific-
ity were calculated by dividing patients into two groups: 
surviving or dead. Univariate and multivariate analyses 
were performed by the Cox proportional hazards model 
using SPSS version 23 (IBM SPSS Statistics; IBM Cor-
poration, Armonk, NY). Only variables with P-value < 
0.05 after the univariate analysis were entered into the 
multivariate analysis. Statistical significance was defined 
as P-value < 0.05.
RESULTS
Patient characteristics
The median follow-up time after recurrence was 21.0 
months (range 1.0–87.0 months). The characteristics of 
these 89 patients with resected p-stage I NSCLC are 
summarized in Table 1. The mean age of the 89 patients 
at recurrence was 74.4 ± 9.3 years (range 34–92 years). 
Sixty-nine patients (77.5%) were male; 20 (22.5%) were 
female. Seventy patients (78.7%) were former or current 
smokers. The mean size was 24.5 ± 10.3 mm (range 
12–50 mm). Fifty-five patients (61.8%) underwent lobec-
tomy and the remaining 34 patients (38.2%) underwent 
sublobar resection including segmentectomy (n = 7) and 
wedge resection (n = 27). The most common pathologi-
cal type of the resected specimens was adenocarcinoma 
in 51 patients (57.3%) and squamous cell carcinoma in 
32 patients (36.0%). The number of patients who were 
diagnosed with presence of vascular invasion was 58 
(65.2%); lymphatic invasion was 76 (85.4%), and pleural 
invasion was 25 (28.1%). 
Analysis of recurrence pattern and post recur-
rence therapy
The patterns of recurrence and the frequency of initial 
recurrent site are listed in Table 2. The median RFI was 
16.8 months (range 1.0–116.0 months). Of 89 patients, 
25 (28.1%) had symptoms at the time of the initial recur-
rence. The mean serum carcinoembryonic antigen (CEA) 
at recurrence was 7.1 ± 7.5 ng/mL (range 0.8–39.5 ng/
mL) (normal range is 0–5.0 ng/mL).
 The pattern of recurrence was locoregional in 22 
(24.7%) and distant in the other 67 (75.3%). Forty-nine 
(55.0%) patients had a single organ metastasis; the other 
40 (45.0%) had multiple organ metastases. The most 
common organs of recurrence were the contralateral 
lung in 42 (48.8%), followed by the ipsilateral thorax in 
22 (24.7%), bone in 18 (20.2%), brain in 12 (13.5%), liver 
in nine (10.1%), pleural effusion/dissemination in five 
(5.6%), and adrenal gland in five (5.6%).
 Twenty-three patients did not receive post recurrent 
therapy. They did not receive the treatment because 18 of 
23 patients were over 80 years old, 3 were performance 
status (PS) > 2 and 2 were rejected treatment. Surgical 
therapy was performed in 7 patients for the recurrence. 
Of these seven patients, 2 underwent surgery alone, 4 
underwent surgery with chemotherapy, and 1 underwent 
surgery with radiation therapy. Of 55 patients who re-
ceived chemotherapy, 21 received EGFR-TKIs therapy. 
Among 21 patients treated with EGFR-TKIs, EGFR mu-
tation was positive in 14 and not examined in 7. EGFR 
mutation was negative in 24 of 34 patients who received 
chemotherapy other than EGFR-TKIs and not tested in 
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Table 1. Characteristics of 89 patients with resected stage I NSCLC
Variable Data
Age at recurrence, yrs (mean ± SD) 74.4 ± 9.3
Sex, n (%) Male 69 (77.5)
Female 20 (22.5)
Smoking history, n (%) Absent 19 (21.3)
Present 70 (78.7)
Tumor size, mm (mean ± SD) 24.5 ± 10.3
Resection type, n (%) Wedge resection 27 (30.3)
Segmentectomy 7 (7.9)
Lobectomy 55 (61.8)
Adjuvant therapy, n (%) Absent 49 (55.1)
Present 40 (44.9)
p-Stage, n (%) IA 43 (48.3)
IB 46 (51.7)
Histological type, n (%) Adenocarcinoma 51 (57.3)
Squamous cell carcinoma 32 (36.0)
Others: 6 (6.7)
       Adenosquamous 3
       LCNEC 3
Vascular invasion, n (%) Absent 31 (34.8)
  Present 58 (65.2)
Lymphatic invasion, n (%) Absent 13 (14.6)
Present 76 (85.4)
Pleural invasion, n (%) Absent 64 (71.9)
 Present 25 (28.1)
EGFR mutation, n (%) Absent 36 (40.4)
Present 15 (16.9)
Not available 38 (42.7)
EGFR, epidermal growth factor receptor; LCNEC, large cell neuroendocrine carci-
noma; NSCLC, non-small cell lung cancer; yrs, years.
the remaining 10. 
Analysis of PRS and prognostic factors
The median PRS interval was 29.0 months, and the 
1-year PRS and 3-year PRS rates were 65.6% and 44.7%, 
respectively. The cut-off values of age, tumor size, RFI 
and CEA was 75 years old (AUC 0.510, 48.5% sensitiv-
ity, 46.7% specificity), 25 mm (AUC 0.656, 51.5% sensi-
tivity, 60.0% specificity), 17 months (AUC 0.318, 39.4% 
sensitivity, 30.0% specificity) and 5.0 ng/mL (AUC 
0.494, 36.4% sensitivity, 73.3% specificity), respective-
ly. The univariate analysis indicated that male sex (P = 
0.035), smoking history (P = 0.034), larger tumor size (> 
25 mm) (P = 0.008), stage IB (P = 0.044), RFI within 17 
months (P = 0.011), presence of symptoms (P = 0.001), 
bone metastasis (P = 0.001), liver metastasis (P = 0.009) 
and not having received any treatment (P < 0.001) were 
significant poor prognosis factors of PRS (Table 3). Re-
garding histological types, squamous cell carcinoma had 
a significantly poor prognostic factor compared to ade-
nocarcinoma [hazard ratio (HR): 2.347, 95% confidence 
shown in Figs. 1B and C, respectively. The patients with 
bone metastasis showed significantly poor survival (P = 
0.004), whereas the patients who underwent treatment 
with EGFR-TKIs showed significantly good survival (P 
= 0.039). The median PRS of the patients with and with-
out bone metastasis were 15.0 months and 44.0 months, 
respectively. The median PRS values of the patients with 
EGFR-TKIs treatment and those without such treatment 
were 49.0 months and 29.0 months, respectively. Among 
45 patients without EGFR-TKIs treatment, EGFR muta-
tion was negative in 27 and not examined in 18. 
DISCUSSION
We analyzed the predictive factors for PRS after com-
plete resection in patients with p-stage I NSCLC. Tumor 
size, RFI and treatment for recurrence were significant 
prognostic factors of PRS in the multivariate analysis. 
For the patients who underwent treatment for recurrence, 
bone metastasis and treatment without EGFR-TKIs 
were significant poor-prognosis factors of PRS in the 
multivariate analysis. Although several studies have 
interval (CI): 1.192–4.201, P = 0.003], 
and tended to have poor prognosis com-
pared to other histological types (LCNEC 
and adenosquamous cell carcinoma) (HR: 
6.998, 95% CI: 1.212–55.621, P = 0.071). 
 The multivariate analysis revealed 
that larger tumor size (> 25 mm) (HR: 
2.271, 95% CI: 1.00–5.16, P = 0.048), RFI 
within 17 months (HR: 1.887, 95% CI: 
0.99–3.60, P = 0.048) and no treatment 
for recurrence (HR: 4.955, 95% CI: 2.44–
10.05, P < 0.001) were the independent 
poor-prognosis factors of PRS (Table 3). 
 Since post recurrence therapy had 
a strong impact on PRS (Fig. 1A), we 
further examined the PRS in the 66 pa-
tients who underwent any type of post 
recurrence therapy. Univariate analysis 
revealed that RFI within 17 months (P 
= 0.017), bone metastasis (P = 0.007), 
liver metastasis (P = 0.018) and treatment 
without EGFR-TKIs (P = 0.040) were 
significant poor-prognosis factors of 
PRS. Multivariate analysis demonstrated 
that bone metastasis (HR: 3.484, 95% 
CI: 1.173–10.350, P = 0.025) and no EG-
FR-TKIs therapy (HR: 2.100, 95% CI: 
0.928–4.754, P = 0.049) were significant-
ly associated with PRS (Table 4). 
 The PRS curves stratified according 
to bone metastasis and EGFR-TKIs are 
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Table 2. Initial site and pattern of recurrence in 89 pa-
tients
Variables Data
Recurrence symptoms, n (%)
  Present 25 (28.1)
  Absent 64 (71.9)
CEA at recurrence, ng/mL (mean ± SD) 7.1 ± 7.5
The median RFI, months (range) 16.8 (1–116)
Initial recurrence site
  Ipsilateral thorax 22
  Lung 42
  Bone 18
  Brain 12
  Liver 9
  Adrenal gland 5
  Pleural effusion/dissemination 5
  Skin 2
  Renal 2
  Colon 2
  Muscle 1
Post-recurrence therapy, n (%)
  None 23 (25.8)
  Surgery alone 2 (2.2)
  Surgery+chemotherapy 4 (4.4)
  Surgery+radiation therapy 1 (1.1)
  Chemotherapy alone 47 (52.8)
  Chemo-radiation therapy 8 (9.0)
  Radiation therapy alone 4 (4.5)
CEA, carcinoembryonic antigen; RFI, recurrence free interval.
demonstrated the PRS rate and predictive factors of PRS 
in resected p-stage I NSCLC patients,2–5 the predictive 
prognostic factors of PRS remain controversial. 
 Although pathologic vascular invasion and pleural 
invasion are known to be prognostic factors for the pa-
tients with stage I NSCLC,15–20 these pathological factors 
had no significant impact on PRS in the present study. 
PRS may be associated with characteristics of recurrent 
lesion, including the biology of the recurrent tumor, RFI, 
recurrent site, the treatment for recurrence, rather than 
with the biological characteristics of primary lung can-
cer. 
 RFI has been reported to be a predictive factor of 
PRS in resected NSCLC.3, 5, 7, 8 In particular, Shimada 
et al. and Song et al. reported that a shorter RFI was a 
poor prognosis factor of PRS in p-Stage I NSCLC, and 
they noted that most of the recurrences occurred within 
24 months of the operation.3, 5 In the present study, the 
proportions of recurrences within 2 and 3 years after 
surgery were 65.2% and 74.2%, respectively, and the 
median RFI was 16.8 months. We observed that an RFI 
≤ 17 months was a predictor for PRS in resected stage 
I NSCLC. Song et al. described that the RFI is a direct 
measure of a patient’s tumor biology.5 In cases of short 
RFIs, there might be systemic micrometastases that 
could not be detected before surgery.
 Several studies have demonstrated that an initial 
recurrent site was a prognostic factor for PRS, which 
agrees with our present finding. Shimada et al. showed 
that bone metastasis was a poor prognostic factor for 
PRS in patients with stage I NSCLC,3 and Yoshino et al. 
also demonstrated that bone metastasis was a marginal 
poor-prognostic factor for PRS in patients with stage 
I-III NSCLC.21 In our present analysis, bone metastasis 
was a significant poor prognostic factor for patients who 
had undergone any post recurrence treatment. It is rel-
atively easy to detect local recurrence and pulmonary 
metastasis by using CT at an early stage, but it is often 
difficult to find the bone and liver metastases. To find 
them, bone scintigraphy, PET and abdominal ultrasound 
are also necessary, but these imaging examinations are 
not routinely performed for surveillance. When bone or 
liver metastases are detected, either of these has already 
caused multiple organ metastases, which is considered 
to be the cause of poor PS. Of the 11 patients with bone 
metastasis, ten had multisite metastasis and six had a PS 
> 2. Failure to undergo systemic chemotherapy due to a 
poor PS is likely to be a factor in poor prognoses.
 The survival benefit of systemic chemotherapy for 
postoperative recurrence remains controversial. Yano et 
al. showed that systemic chemotherapy had no signifi-
cant effect on prognosis after local recurrence, whereas 
radiation therapy improved the survival after local recur-
rence.22 On the other hand, several studies demonstrated 
that patients with stage I NSCLC who received post 
recurrence therapy had a significantly better PRS than 
those who didn’t receive post recurrence therapy.2, 3, 5 Our 
present findings also showed that post recurrence ther-
apy was a significant prognostic factor after recurrence. 
In our study, post recurrence therapy with surgery did 
not contribute to the PRS. The reason may be that the 
number of patients who received post recurrence surgery 
therapy was too small to provide any supportive data in 
terms of PRS benefit. To examine the survival benefit of 
post recurrence therapy with chemotherapy and surgery, 
multicenter large-scale analyses are needed.
 Several studies reported a relationship between the 
use of EGFR-TKIs therapy and PRS in patients with 
recurrent NSCLC.3, 11, 13 Takanaka et al. and Kudo et al. 
noted that post recurrence therapy with EGFR-TKIs 
prolonged the PRS in resected stage I–IV NSCLC pa-
tients.11, 13 Similarly, Shimada et al. reported that EG-
FR-TKIs therapy improved the PRS in resected stage I 
NSCLC patients.3 In this study, there were 14 patients 
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Table 3. Univariate and multivariate analyses for post recurrence survival in 89 patients with resected p-stage I 
NSCLC
Variables Univariate MultivariateP-value HR (95% CI) P-value
Sex (female vs. male) 0.035 0.983 (0.156–6.174) 0.983
Age at recurrence (≤ 75 vs. > 75 yrs) 0.160 – –
Smoking history (yes vs. no) 0.034 2.314 (0.30–17.86) 0.421
Tumor size (> 25 mm vs. ≤ 25 mm) 0.008 2.271 (1.00–5.16) 0.048
Resection type (lobectomy vs. sublobar) 0.247 – –
Adjuvant (present vs. absent) 0.911 – –
p-Stage (IA vs. IB) 0.044 0.912 (0.38–2.17) 0.835
Histological type – –
     Adenocarcinoma 0.001 0.647 (0.32–1.297) 0.220
     Squamous cell carcinoma – –
     Others 0.055 0.150 (0.02–1.16) 0.069
Vascular invasion (present vs. absent) 0.543 – –
Lymphatic invasion (present vs. absent) 0.656 – –
Pleural invasion (present vs. absent) 0.795 – –
RFI (≤ 17 M vs. > 17 M) 0.011 1.887 (0.99–3.60) 0.048
Recurrence pattern (distant vs. locoregional) 0.212 – –
CEA at recurrence (> 5 vs. ≤ 5) 0.564 – –
Symptom at recurrence (present vs. absent) 0.001 1.026 (0.49–2.15) 0.945
Pulmonary metastasis (present vs. absent) 0.168 – –
Brain metastasis (present vs. absent) 0.618 – –
Bone metastasis (present vs. absent) 0.001 2.085 (0.86–5.04) 0.103
Liver metastasis (present vs. absent) 0.009 1.256 (0.49–3.24) 0.637
Post-recurrence therapy (absent vs. present) < 0.001 4.955 (2.44–10.05) < 0.001
CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; M, months; NSCLC, non-small cell lung cancer; RFI, recur-
rence free interval; yrs, years.
Table 4. Univariate and multivariate analyses for post-recurrence survival in 66 patients who underwent post-re-
currence therapy
Variables Univariate MultivariateP-value HR (95% CI) P-value
Recurrence pattern (distant vs. locoregional) 0.206 – –
CEA at recurrence (> 5 vs. ≤ 5) 0.534 – –
RFI (≤ 17 M vs. > 17 M) 0.017 1.614 (0.745–3.496) 0.225
Pulmonary metastasis (present vs. absent) 0.860 – –
Brain metastasis (present vs. absent) 0.870 – –
Bone metastasis (present vs. absent) 0.007 3.484 (1.173–10.350) 0.025
Liver metastasis (present vs. absent) 0.018 1.271 (0.386–4.182) 0.693
Treatment after recurrence with chemotherapy 0.241 – –(absent vs. present)
Treatment after recurrence with surgery 0.293 – –(absent vs. present)
Treatment after recurrence with EGFR-TKIs 0.040 2.100 (0.928–4.754) 0.049(absent vs. present)
CEA, carcinoembryonic antigen; CI, confidence interval; EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; HR, 
hazard ratio; M, months; RFI, recurrence free interval.
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who were EGFR mutation positive in the treatment in-
tervention group, and all patients received EGFR-TKIs 
therapy as first-line treatment. Seven patients received 
EGFR-TKIs therapy although their EGFR mutation 
status was unknown. Our study also showed that EG-
FR-TKIs therapy provided a better survival benefit than 
post recurrence therapy without EGFR-TKIs. The medi-
an PRS of our patients who received EGFR-TKIs thera-
py was 49.0 months, whereas that of the patients without 
EGFR-TKIs therapy was 29.0 months. Survival was con-
sidered to be prolonged by administering EGFR-TKIs to 
the patients with EGFR mutation. Therefore, especially 
in adenocarcinoma, it is important to confirm the EGFR 
mutation status after recurrence and not to miss the pa-
tients who can receive EGFR-TKIs treatment.
 There are several limitations associated with our 
study. First, patient selection bias and lead-time bias 
might be obligatory due to the retrospective single-insti-
tute nature of the study. Second, distinguishing between 
second primary lung cancer and recurrent pulmonary 
metastasis was difficult. Only 43.0% of our patients 
underwent a pathological evaluation of pulmonary 
metastasis. Even though pathological specimens were 
obtained, a definitive diagnosis could be difficult under 
the current morphological and immunohistochemical 
analyses. Third, there was a selection bias for the treat-
ment. Curative intent therapy is difficult to perform in 
patients with a poor PS and/or extensive disease. Fourth, 
we could not examine the EGFR mutation status in all 
recurrent cases. Lastly, a lack of uniformity in screening 
for cancer recurrence might have influenced the detec-
tion of recurrent disease and RFI.
 In conclusion, our analyses showed that tumor size, 
RFI, and post recurrence therapy were prognostic fac-
tors for PRS. In the patients who underwent treatment 
after recurrence, bone metastasis and treatment with 
EGFR-TKIs were independent prognostic factors for 
PRS. Although further validation of our findings is nec-
essary, this information is important for the design of 
future clinical trials for therapy after recurrence among 
NSCLC patients.
Fig. 1. (A) PRS curves stratified according to post-recurrence ther-
apy. PRS curves with post-recurrence therapy stratified according 
to bone metastasis (B) and EGFR-TKIs (C). EGFR-TKIs, epider-
mal growth factor receptor tyrosine kinase inhibitors; PRS, post 
recurrence survival.
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